|
|
|
|
Integrating Infrastructure for Clinical Trials
eClinical Technologies Medidata on the cloud, ‘omics, and personalized medicine. By Kevin Davies January 10, 2012 | Glen de Vries thought he would be teaching biology or chemistry in college, but
|
|
Survey Says: Tool Up for Smarter Clinical Studies
Bio-IT World | Separate industry surveys by information technology research and advisory firm Gartner and global software company ClearTrial make a strong case for clinical resource management tools in the cost-cutting arsenal of biopharmaceutical and medical device companies.
|
|
An Insider Perspective on PAREXEL
Bio-IT World | Mark Goldberg, PAREXEL’s chief operating officer, recently sat down with Bio•IT World chief editor Kevin Davies to discuss the importance of convergence in Perceptive Informatics’ suite of eClinical offerings, and to share his insights on the future opportunities, trends, and challenges facing the industry.
|
|
Tooling up for Smarter Studies
Two industry studies found need for appropriate trial planning and tools. By Deborah Borfitz Novemer 15, 2011 | Separate industry surveys by information technology research and advisory firm Gartner and global software company ClearTrial make a strong case for clinical
|
|
An Inside Perspective on PAREXEL
One of the oldest clinical research organizations discusses technology and changes in the industry. November 15, 2011 | Mark Goldberg, PAREXEL’s chief operating officer, has been with the company since 1997 when he started the CRO’s medical imaging business. A
|
|
Seize the New: Laying the Clinical Genomics Pipeline in Wisconsin
Liz Worthey’s “smart software” crucial to integrating genome sequencing in clinic. By Kevin Davies September 27, 2011 | On Saturday June 27, 2009, a pediatric gastroenterologist named Alan Mayer at the Medical College of Wisconsin (MCW) sat at his computer
|
|
Trials at the Point-of-Care
Veterans Affairs tries new method for treatment comparison trials. By Deborah Borfitz September 27, 2011 | A new type of clinical trial now undergoing testing at the Veterans Affairs (VA) Boston Healthcare System will likely be of interest to emerging
|
|
Stigmergy, Anyone?
By Ernie Bush September 27, 2011 | The Bush Doctrine | Stigmergy is currently defined in Wikipedia as “A mechanism of indirect coordination between agents or actions. The principle is that the trace left in the environment by an action
|
|
September-October New Products
Versatile NMRAgilent Technologies has announced the release of VnmrJ 3.2, an enhanced version of their software for nuclear magnetic spectroscopy. VnmrJ 3.2 offers a data station version that runs on Windows, Mac, and Linux. This enables users to analyze NMR
|
|
End of Summer Rant: CDER Must Have Clinical Trial Reform
By John Russell September 27, 2011 | The Russell Transcript | It’s not always easy to know what to make of FDA initiatives, particularly at the time they are announced. Some are modest and administrative in nature (Fast Track, 2009)
|
Turning Genomics Data into Practical Insight With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can: - Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines.
- Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image).
Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands.
New Complimentary Market Survey… Collaborations and Communications Within Drug Discovery Research This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns. An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
Scientific Software Engineer
Boston MA
$70,000 to $95,000
Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET.
Apply at http://jobs.tessella.com
Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes. As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers. This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions. It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply
Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules. It is therefore suitable for use in a variety of markets including scientific research and clinical applications. As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team. The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market. This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company. Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial leadership, who wish to apply a fresh approach to existing markets. Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries. We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products. Click to Apply
|
|
|